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p21-Encoding Cdkn1aPiperlongumine (PL), isolated from the fruit of Long pepper, Piper longum, is a cancer-inhibiting
compound that selectively kills tumor cells while sparing their normal counterparts. Here we evaluated
the efﬁcacy with which PL suppresses malignant B cells derived from a newly developed, double-trans-
genic mouse model of human endemic Burkitt lymphoma (BL), designated mCD40-LMP1/iMycEl. PL
inhibited tumor cell proliferation in a concentration-dependent manner and induced apoptosis of
neoplastic but not normal B cells. Treatment with PL resulted in downregulation of EBV-encoded
LMP1, cellular Myc, constitutive NF-jB activity, and a host of LMP1-Myc-NF-jB-regulated target genes
including Aurka, Bcat1, Bub1b, Ccnb1, Chek1, Fancd2, Tfrc and Xrcc6. Of note, p21Cip1-encoding Cdkn1a
was suppressed independent of changes in Trp53mRNA levels and p53 DNA-binding activity. Considering
the central role of the LMP1–NF-jB–Myc axis in B-lineage neoplasia, these ﬁndings further our under-
standing of the mechanisms by which PL inhibits B-lymphoma and provide a preclinical rationale for
the inclusion of PL in new interventions in blood cancers.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction Hallmarks of human endemic BL include both infection with Ep-Piperlongumine (PL), a constituent of Long pepper, Piper lon-
gum, demonstrates tumor-inhibiting, immunomodulatory, and
antioxidant properties [1]. We were ﬁrst to report that PL kills
the high-grade B-cell tumor, Burkitt lymphoma (BL), but leaves
normal B lymphocytes alive [2]. This ﬁnding added BL to a long list
of cancer cell lines – including melanoma as well as bladder, breast
and lung tumors – in which low micromolar concentrations of PL
exhibit high levels of cytotoxicity [3]. To translate the promise of
PL into actionable approaches to cancer therapy and prevention,
it is necessary to elucidate the biological mechanism by which
the compound inhibits malignant growth.stein Bar virus (EBV) followed by expression of EBV-encoded LMP1
[4] and deregulation of the cellular oncoprotein MYC [5]. Both
LMP1 andMYC promote B-cell proliferation and survival, using dis-
tinct but interconnected pathways [6,7]. LMP1 functionally mimics
signaling of CD40 [4], a key downstream event of which is activa-
tion of the nuclear factor kappa-B (NF-jB) family of transcription
factors, which regulate numerous target genes governing B-cell
activation, proliferation and protection from apoptosis [8]. Consti-
tutive NF-jB signaling is key to the development and therapy
resistance of many cancers, including B-cell lymphoma [9–11].
Cooperative functions of LMP1, NF-jB and MYC have been well
documented in B-cell lymphoma; e.g., LMP1 activates NF-jB
[12]; NF-jB is a positive regulator of MYC expression [13,14];
and MYC and NF-jB are required for EBV/LMP1-driven tumors
[15]. Developing targeted drugs for inhibiting the LMP1–NF-jB–
MYC pathway is a priority for research on EBV-associated lympho-
mas and other cancers.
We recently developed a double-transgenic mouse model of hu-
man BL, designated mCD40-LMP1/iMycE, which lends itself to the
testing of pharmacological inhibitors of LMP1–NF-jB–Myc-driven
B-cell tumors. Mice harboring the iMycEl [16] and mCD40-LMP1
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cell lines can be readily established. Here, we took advantage of
one of these cell lines, Hal2G1, to evaluate the possibility that PL
kills BL-like tumors by inhibiting the LMP1–NF-jB–Myc pathway.
Treatment with PL resulted in strong pathway suppression, leading
to the downregulation of critical LMP1–NF-jB–Myc target genes
including Aurka, Bcat1, Bub1b, Ccnb1, Chek1, Tfrc, Fancd2, Xrcc6
and Cdkn1a. Interestingly, PL-dependent inhibition of Cdkn1a,
which encodes the p53 target and cell cycle inhibitor, p21CIP1,
was not associated with changes in TP53 mRNA or DNA-binding
activity of p53. These results further our understanding of the
mechanism by which PL kills malignant B cells and underline the
utility of strain mCD40-LMP1/iMycEl mice for PL’s envisioned pre-
clinical assessment in vivo.2. Materials and methods
2.1. Mice and tumor cell lines
C57BL/6 (B6) mice containing the mCD40-LMP1 [17] or iMycEl
[16] transgene were intercrossed to generate double-transgenic
mCD40-LMP1/iMycEl mice. Tumor cell lines, designated Hal, were
generated from BL-like tumors harvested from these mice. Hal2G1
was derived from a tumor that had been propagated in vivo (ﬁrst
transplant generation or G1), whereas Hal1G0 was derived from
a primary tumor (G0) from a different mouse. WEHI231 mouse B
lymphoma cells were purchased from ATCC (ATCC, Manassas,
VA). iMycEl-1 lymphoblastic B-cell lymphoma (LBL) cells have
been described previously [18]. All cell lines were maintained in
RPMI 1640 supplemented with 10% heat-inactivated fetal bovine
serum, at 37 C in a humidiﬁed 5% CO2 incubator. Normal splenic
B cells were isolated from B6 mice using CD45R (B220) MACS
beads (Miltenyi Biotec, Auburn, CA). Human B-lymphocytes were
isolated from blood donor PBMCs (peripheral blood mononuclear
cells), using centrifugation in a Ficoll-Paque density gradient
(30 min, 400  g) followed by fractionation on CD45R (B220) MACS
columns.
2.2. Cellular and molecular assays
PL was purchased from Indoﬁne (Hillsborough, NJ) and dis-
solved in DMSO prior to use. The ﬁnal concentration of DMSO
never exceeded 0.1%. MTS, trypan blue exclusion (TBE) and propi-
dium iodide (PI) staining assays were employed to evaluate prolif-
eration and survival of B cells. Expression levels of genes of interest
were measured with the help of reverse transcription (RT) poly-
merase chain reaction (PCR) and quantitative PCR (qPCR). DNA
binding activity of Myc, NF-rB and p53 was determined by electro-
phoretic mobility shift assay (EMSA). Statistical analysis used Stu-
dent’s t test; p < 0.05 was considered signiﬁcant. Additional details
are provided in the Supplementary materials section.3. Results
3.1. PL inhibits growth and proliferation of mouse B lymphoma cells
To evaluate the inhibitory effect of PL on mouse B-cell lym-
phoma, MTS assays were performed using Hal2G1, Hal1G0,
iMycEl-1 and WEHI231 cells treated with increasing concentra-
tions of PL (2.5–20 lM) for 24 h. Fig. 1A shows that PL inhibited
4 of 4 cell lines in a concentration-dependent manner. There were
small differences in the susceptibility to the drug, reﬂected by dif-
ferent IC50 values: Hal2G1 cells were most sensitive to PL
(IC50 = 5.1 lM), followed by Hal1G0 (7.0 lM), iMycEl-1 (7.6 lM)
and the least sensitive line, WEHI231 (9.0 lM). Because ofHal2G1’s exquisite sensitivity to PL, the cell line was chosen as
principal model system for the studies presented below.
3.2. PL selectively induces apoptosis in mouse B lymphoma cells
To compare mouse B lymphoma with normal splenic B cells, we
repeated the study depicted in Fig. 1A after inclusion of B220+
splenocytes from inbred B6 mice, using trypan blue exclusion to
distinguish viable and dead cells. Fig. 1B shows that treatment
with PL caused signiﬁcant death in all lymphomas but not normal
B cells. In agreement with that, ﬂow cytometric analysis of DNA
content of PI-stained Hal2G1 and normal B cells showed a greater
than four-fold increase in the apoptotic sub-G1 fraction of Hal2G1
cells treated with 5 lM PL, yet only a negligible increase in normal
B cells (Fig. 1C). Apoptotic death was conﬁrmed by the detection of
fragmented DNA in PL-treated Hal2G1 cells, which was not seen in
normal B cells (Fig. 1D). These results demonstrated that PL selec-
tively induced apoptosis in malignant but not normal B cells.
3.3. PL inhibits Myc and NF-jB activity
RT-PCR (Fig. 2A) and qPCR (Fig. 2B) were used to determine the
expression of LMP1 and Myc in Hal2G1 cells and B-cell tumors ob-
tained from 6 different mCD40-LMP1/iMycEl-transgenic mice.
Normal B cells were used as control. The levels of Myc message
were comparable in Hal2G1 cells and B-lymphomas by qPCR
(Fig. 2B bottom), but LMP1 was signiﬁcantly higher in the cell line
(Fig. 2B top). The latter was due, at least in part, to heterogeneities
in LMP1 expression in the B-lymphomas (Fig. 2A). Next, EMSA was
used to demonstrate the DNA-binding activity of Myc and NF-jB to
their speciﬁc target sequences (Fig. 2C and D). Hal2G1 cells exhibit
high levels of that activity, rendering the cell line a good model for
inhibition studies using PL. Indeed, PL attenuated the expression of
Myc (Fig. 2E bottom) and LMP1 (Fig. 2E top) in Hal2G1 cells, sug-
gesting that PL either reduces activity at the MHC II Ea promoter
driving mCD40-LMP1 expression [17] or somehow negatively reg-
ulates stability of the transgenic transcript. This was not further
investigated. More importantly, PL reduced the DNA-binding activ-
ity of Myc and NF-jB (Fig. 2F and G) in Hal2G1 cells, suggesting
that PL-dependent apoptosis is mediated by inhibition of the
LMP1–NF-jB–Myc axis.
3.4. Treatment with PL results in downregulation of LMP1–NF-jB–
Myc-dependent target genes
We next evaluated the expression of 40 putative LMP1–NF-jB–
Myc targets to identify genes involved in PL-dependent inhibition
of growth and survival of lymphoma cells. mRNA levels of Aurka,
Bcat1, Bub1b, Ccnb1, Chek1, Fancd2, Tfrc and Xrcc6 were signiﬁ-
cantly elevated in mCD40-LMP1/iMycEl tumors and Hal2G1 cells
compared to normal B splenocytes (Fig. 3A), but this was not the
case for Racgap1 (right column, center) and genes encoding Pax5,
Blimp1, Xbp1, Bcl2, Bcl-xL and two cytokines, IL-6 and IL-10 (Suppl.
Fig. 2). Treatment of Hal2G1 cells with PL resulted in downregula-
tion of all overexpressed genes mentioned above, yet upregulation
of Racgap1 (Fig. 3B). The latter was also seen in 4 of 4 human BL
lines and mouse iMycEl-1 cells (Suppl. Fig. 1). These results indi-
cated that treatment with PL suppresses a set of LMP1–NF-jB–
Myc-regulated target genes known to be important for B cell acti-
vation and survival.
3.5. PL-dependent downregulation of p21 is not dependent on p53
A gene of special interest that was also elevated in mCD40-
LMP1/iMycEl-driven lymphoma and Hal2G1 cells relative to nor-
mal B220+ splenocytes was Cdkn1a (Fig. 4A top). This gene encodes
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Fig. 1. PL-dependent growth inhibition and apoptosis. (A) MTS assay, a measure of metabolic activity, was used as surrogate for cell proliferation. Cells (106/ml) were treated
with the indicated concentrations of PL for 24 h. Results were normalized to cells treated with DMSO only (solvent control). Error bars indicate standard deviations of the
mean determined in a representative experiment performed in triplicate. IC50 of PL was determined for each cell line and used for all following experiments unless otherwise
stated. (B) Cells were treated with PL as described in panel A and the fraction of dead cells was determined with the assistance of the TBE assay. (C) Normal B splenocytes
(black bars) or Hal2G1 cells (white bars) were treated for 24 h with 5 lM PL or left untreated (DMSO only). Cells were stained with PI (propidium iodide) and subjected to
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Fig. 2. PL inhibits the LMP1–NF-jB–Myc pathway. (A) RT-PCR analysis of LMP1 and Myc expression in normal splenic B cells (lane 1), B-cell tumors obtained from 6 different
mCD40-LMP1/iMycEl-transgenic mice (lanes 2–7) and Hal2G1 cells (lane 8). The housekeeping gene, Actb, was used as control. (B) qPCR analysis of the samples from panel A.
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cells. (C) EMSA of nuclear extracts prepared from normal B cells, lymphoma tissues and cell lines as indicated. Myc DNA-binding activity is indicated by labeled arrowhead.
(D) EMSA of the samples from panel C. NF-jB DNA-binding activity is indicated by thick vertical line. (E) PL-dependent reduction of LMP1 and Myc mRNA levels in Hal2G1
cells, as determined by qPCR. Cells were cultured in presence (+) or absence () of PL for 24 h. (F) NF-jB DNA-binding activity in Hal2G1 cells treated with PL as shown in
panel E (+) or left untreated (). (G) Myc DNA-binding activity in Hal2G1 cells treated with PL as shown in panel E (+) or left untreated ().
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the Trp53-encoded tumor suppressor, p53. Unlike Cdkn1a, Trp53
was not elevated in malignant B cells (Fig. 4A bottom). Just as for
proliferation-associated genes, such as Aurka, Bub1b and Ccnb1,treatment of Hal2G1 with PL reduced p21 expression (Fig. 4B
top) but had no effect on the level of Trp53 message (Fig. 4B bot-
tom) or p53 DNA-binding activity (Fig. 4C). This phenomenon also
held true in several other human BL cell lines and transgenic
A 
0
1
2
3
4 Aurka 
0
2
4
6
Ccnb1 
B6
.S
pl
 B
 
m
CD
40
-
LM
P1
/i
M
yc
Eμ
 
H
al
2G
1 
0
5
10
15 Bcat1 
0
2
4
6
8 Bub1b 
Fo
ld
 g
en
e 
ex
pr
es
si
on
 c
ha
ng
e 0
1
2
3
4 Chek1 
0
1
2
3 Fancd2 
0
1
2
3 Tfrc 
0
1
2 Racgap1 
Fo
ld
 g
en
e 
ex
pr
es
si
on
 c
ha
ng
e 
0
1
2
3
4
5 Xrcc6 
B6
.S
pl
 B
 
m
CD
40
-
LM
P1
/i
M
yc
Eμ
 
H
al
2G
1 
B 
0
1
2
3
4 Aurka 
0
5
10
15 Bcat1 
0
1
2
3
4 Bub1b 
PL - + 0
1
2
3 Ccnb1 Fo
ld
 g
en
e 
ex
pr
es
si
on
 c
ha
ng
e 0
1
2
3
4 Chek1 
0
1
2
3 Fancd2 
0
2
4 Tfrc 
0
1
2
3 Racgap1 
0
1
2
3
4 Xrcc6 
PL - + 
Fo
ld
 g
en
e 
ex
pr
es
si
on
 c
ha
ng
e 
Fig. 3. PL-dependent expression changes of LMP1–NF-jB–Myc target genes. (A) qPCR results indicating elevated expression of all indicated genes except Racgap1 in
lymphomas from mCD40-LMP1/iMycEl mice (n = 6) or Hal2G1 cells relative to normal B220+ splenocytes. Target gene expression was normalized to Hprt and converted to
fold gene expression change by dividing the results from lymphomas to Hal2G1 cells to the value of normal B cells. Error bars represent the standard deviation of the mean
from triplicate measurements. (B) qPCR results showing that compared to Hal2G1 cells left untreated (), all indicated genes except Racgap1 were down regulated upon
treatment with PL for 24 h (+). Racgap1 was up regulated.
B A 
B6
. S
pl
 B
 
D
M
SO
 
PL
 5
uM
 
Hal 2G1 
◄ p53
C 
0
2
4
6 p21
0
1
2 p53
B6
.S
pl
 B
 
m
CD
40
-
LM
P1
/i
M
yc
Eμ
 
H
al
2G
1 
Fo
ld
 g
en
e 
ex
pr
es
si
on
 c
ha
ng
e 
0
1
2 p53
0
2
4
6 p21
PL - + 
Fo
ld
 g
en
e 
ex
pr
es
si
on
 c
ha
ng
e 
Fig. 4. Signiﬁcant PL-dependent downregulation of p21-encoding Cdkn1a message
in the face of unchanged p53 DNA-binding activity. (A) qPCR results indicating
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ings will be the subject of a separate report. In iMycEl-1 cells, how-
ever, p21 and p53 were co-repressed (Supplementary. Fig. 3),
suggesting that discordant regulation of the two genes in Hal2G1
may be caused by LMP1. These results, understood with the knowl-
edge that the p21 promoter has NF-jB binding sites and can be
regulated by p50/RelB [19], suggest that p21 could function to pro-
mote tumor growth without a change in p53 activation.
4. Discussion
Due to its demonstrable selectivity in cancer cells, PL has re-
cently garnered much interest as an anti-cancer agent [2,3]. Thestudy presented here extends previous reports on PL in cancer re-
search to a newly developed mouse model of human EBV-associ-
ated endemic BL, mCD40-LMP1/iMycEl, in which BL-like tumors
develop predictably in presence of a normal immune system.
Treatment with PL resulted in growth inhibition and selective kill-
ing of mouse BL-like cells including Hal2G1, but left normal splenic
B cells alive. PL-induced cytotoxicity likely relied on a mechanism
that includes suppression of LMP1–NF-jB–Myc target genes
known to sustain cell proliferation and survival. We also speculate
that the p53-independent inhibition of the survival-enhancing
p21–Fancd2–Xrcc6 pathway is part of this mechanism. Although
preliminary at this juncture, our ﬁndings provide a strong rationale
for the continuing preclinical evaluation of PL, including determi-
nation of efﬁcacy with which the compound inhibits mCD40-
LMP1/iMycEl-driven B-cell tumors in mice.
LMP1–NF-jB–Myc signaling governs the transcription of hun-
dreds of target genes, of which we examined a subset of 40 genes
using qPCR. Aurka, Bcat1, Bub1b, Ccnb1, Chek1, Fancd2, Tfrc and
Xrcc6 all exhibited elevated expression in BL-like tumors, as well
as remarkable downregulation upon exposure to PL. Human homo-
logues of these genes are all involved in MYC-dependent cancer
development and/or acquisition of drug resistance in patients with
cancer. For example, in human and mouse B-cell lymphomas, AUR-
KA is positively regulated by MYC at both the transcriptional and
protein levels [20]. BCAT1, also a direct target of MYC, is expressed
at signiﬁcantly higher levels in tumor tissues than in controls [21].
AURKA, BUB1B and CCNB1, three regulators of cell cycle progres-
sion, have been implicated as key upregulated genes during EBV-
induced transformation of B-lymphocytes [22]. Regulation of
CHK1 and CHK2 by MYC promotes radioresistance in a stem cell-
like population of nasopharyngeal carcinoma [23]. TFRC-encoded
transferrin receptor is a critical downstream target of MYC in
B-cell lymphoma [24]. Our ﬁnding that all these genes were
overexpressed in BL-like tumors but coordinately downregulated
upon treatment with PL implicates them as effector genes of
the LMP1–NF-jB–Myc axis of great potential relevance for the
treatment and prevention of B-cell neoplasia.
In contrast to the genes discussed above, Racgap1 was ex-
pressed at low levels in BL-like cells but signiﬁcantly induced upon
664 S.-S. Han et al. / Biochemical and Biophysical Research Communications 436 (2013) 660–665treatment with PL. Little is known about the biological function of
Racgap1 in B-lymphoma, but its value as biomarker for early recur-
rence and heightened aggressiveness of solid cancers is increas-
ingly being recognized [25–27]. Racgap1, a positive regulator of
Rac activity, has been reported to play an important role in cytoki-
nesis [28], differentiation of myeloid cells [29] and, interestingly,
increased production of reactive oxygen species (ROS) [30]. The
latter provides an intriguing parallel to the main mechanism by
which PL is thought to kill solid cancers; i.e., drug-induced surge
in ROS levels [3]. It is therefore possible that in BL-like tumors,
PL-dependent killing relies in part on Racgap1-mediated ROS pro-
duction. This warrants additional study.
Of special interest in our subset of 40 LMP1–NF-jB–Myc target
genes were Cdkn1a, Fancd2 and Xrcc6. These genes were jointly
over-expressed in BL-like tumors and jointly suppressed following
treatment with PL. We postulate that these genes contribute to the
maintenance of BL-like cells in two ways: evasion of apoptosis and
enhanced repair of DNA damage. In support of this theory, Cdkn1a-
encoded p21 promotes leukemia by a complex mechanism that
includes enhanced DNA repair and prevention of p53-induced
apoptosis [31]. Consistent with that, lymphomas arising in p21-
deﬁcient mice exhibit unusually high rates of apoptosis [32].
Fancd2 and the Ku70-encoding Xrcc6 gene are key players in the
Fanconi anemia/early-onset breast cancer (FA/BRCA) DNA repair
pathway and the canonical DNA double-strand break repair path-
way, respectively. Interestingly, Cdkn1a, Fancd2 and Xrcc6 are all
subject to regulation by NF-jB: p21 is transcriptionally regulated
by RelB [19], which is important, for example, for TNFa-treated
cells protected from UV induced-apoptosis by NF-jB-dependent
activation of p21 [33]; NF-jB-mediated expression of Xrcc6 gov-
erns, in part, proliferation of some cell types [34]; p50/RelB regu-
lates transcription of Fancd2, along with that of other genes, in
the FA/BRCA pathway [35]. These ﬁndings support the hypothesis
that PL-dependent killing of BL-like tumors is effected, at least in
part, by downregulation of Cdkn1a, Fancd2 and Xrcc6.
Given that two hallmarks of cancer are sustained proliferation
and evasion of apoptosis [36], our data suggest that LMP1–NF-
jB–Myc-driven expression of Aurka, Bub1b and Ccnb1 is important
for maintaining the former, whereas expression of Cdkn1a, Fancd2,
Xrcc6 and perhaps Chek1 enables the latter in BL-like tumors. Much
more work is necessary to better deﬁne the contributions of each
of these genes to tumor development and treatment response.
However, PL appears to target both hallmarks of cancer, lending
credence to the proposition that the compoundmay afford new ap-
proaches to the chemoprevention and treatment of blood cancers.
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